MedTrace Logo

Salvaged Red Blood Cell Transfusion During Pancreatic Adenocarcinoma Operations

NCT07598357 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-05-20

No results posted yet for this study

Summary

The purpose of this study is to prospectively study the safety of salvage red blood cell (sRBC) transfusion during pancreatic surgery.

Primary Objective:

1. To summarize rates and timing of septic adverse events (AE) for patients who receive sRBC or aRBC transfusions within 72 hours of peri-operative transfusion.
2. To summarize rates and timing of transfusion related AEs for patients who receive sRBC or aRBC transfusions within 72 hours of peri-operative transfusion.
3. To summarize rates and timing of AEs in the first 7 post-operative days.

Secondary Objectives:

1. To summarize the number of units of aRBC transfused post operative day (POD) #0 after sRBC transfusion in the operating room.
2. To summarize the number of units of aRBC transfused POD#1-7 after sRBC transfusion the operating room, in the absence of overt post-operative hemorrhage.

Conditions

  • Pancreatic Surgery

Interventions

DEVICE

The Fresenius Kabi C.A.T.S®plus Continuous AutoTransfusion System

A cell salvage device will be utilized to collect all spilled blood during the course of the operative resection and vascular reconstruction.

Sponsors & Collaborators

Principal Investigators

  • Michael D. Kluger, MD, MPH · NYU Langone Health

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2028-05-31
Completion
2031-06-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07598357 on ClinicalTrials.gov